Doctor’s offices and hospitals meticulously clean the nondisposable medical equipment they repeatedly use. Equipment that cannot be heat-sterilized must be cleaned with powerful disinfectants. Michelle Ozbun, PhD, an international expert on viruses, wanted to know how effective those disinfectants really are.
Ozbun and her team developed a way to measure how many infectious human papillomavirus particles are left on a surface after it has been disinfected. They found that disinfectants approved for use on medical devices work well, and they recently published their work online in The Lancet journal EBioMedicine.
Ozbun is a professor of Obstetrics & Gynecology and of Molecular Genetics & Microbiology at The University of New Mexico. Her research focuses on HPV, which causes more than 90% of cervical and anal cancers and more than 70% of vaginal and throat cancers, according to the Centers for Disease Control and Prevention.
She explains that HPV particles, like all viruses, need to invade a cell in order to produce copies of themselves. And to invade a cell, the virus particle’s capsid must be intact.
The capsid is the outer shell of a virus particle. It is made of viral proteins and encloses the virus’s genetic material, which encodes those proteins. Some viruses, called enveloped viruses, have a layer of fat-like molecules covering the viral proteins.
“Coronavirus and HIV and herpesvirus are all enveloped viruses,” Ozbun says. “They’re much more susceptible to drying out on a surface. And if they dry out, they’re not infectious.”
Viruses like HPV, poliovirus and norovirus have capsids made of just proteins, which means they can remain on surfaces for a long time without becoming inactivated, Ozbun says. “And so,” she says, “they’re much harder to inactivate by disinfectants as well.”
Because HPV does not kill cells, the only way to detect its presence — until now — has been to take a sample of cells, grind them up and search the genetic material for the virus’ genes.
“When people in the field look to see if people have HPV,” Ozbun says, “they’re really just detecting the viral genomes that are there. They don’t know [whether] these viral genomes are packaged inside the capsid.” And once the cells have been ground up, counting the number of intact HPV particles becomes impossible.
An additional problem with the grinding method, Ozbun explains, is that the insides of the cells are mixed together. There’s no way to tell if many cells in the sample are infected with a low level of virus products or if only a few cells are infected with a lot of virus products.
Ozbun needed more sensitive methods, so she created them.
First, Ozbun and her team obtained viral samples from three sources. They grew HPV particles in Ozbun’s lab, they obtained HPV samples from another lab, and they collected HPV samples from patients in New Mexico. Next, they infected cells in a lab with the viral samples. But then they did something different: instead of grinding up the cells, they added a stain that binds to viral RNA and took images of the cells.
Ozbun’s images show intact cells with viral RNA inside. Using sophisticated microscopic techniques developed at the UNM Comprehensive Cancer Center, she and her team are able to count how many cells are infected, allowing them to calculate how many virus particles were present.
Using their images and counting methods, Ozbun and her team were able to show that commonly used disinfectants reduce the number of viral particles by at least 10,000 times. They showed that the disinfectants had similar results regardless of the viral source. And they showed that their methods were sensitive over the range of particles that most hospitals and doctors’ offices normally encounter.
Her new method, says Ozbun, “is an important way of differentiating how much nucleic acid is there, versus what’s really infectious. This is the only way that we can tell the number of infectious particles.”
Ozbun explains further that many cleaning procedures call for equipment to be washed before being disinfected. Washing gets rid of many infectious particles before the disinfectant is used.
The result, she says, is that hospitals and doctors’ offices “have an even higher level of confidence that [they’re] not going to expose patients to virus that’s left over from someone else.”
About Michelle Ozbun, PhD
Michelle Ozbun is a professor in the departments of Obstetrics & Gynecology and Molecular Genetics & Microbiology. She is The Maralyn S. Budke Endowed Professor in Viral Oncology and co-leads the Cellular and Molecular Oncology Research Program at the UNM Comprehensive Cancer Center.
Paper Reference
“Infectious titres of human papillomaviruses (HPVs) in patient lesions, methodological considerations in evaluating HPV infectivity and implications for the efficacy of high-level disinfectants” was published online in January 2021, in EBioMedicine by The Lancet. Authors are: Michelle A. Ozbun, PhD; Virginie Bondu, MA; Nicole A. Patterson, BS; Rosa T. Sterk, BS; Alan G. Waxman, MD; Erica C. Bennett, MD; Rohini McKee, MD; Ankur Sharma, MD; Jeremy Yarwood, PhD; Marc Rogers, PhD; and Gary Eichenbaum, PhD.
About the UNM Comprehensive Cancer Center
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its 146 board-certified oncology specialty physicians include cancer surgeons in every specialty (abdominal, thoracic, bone and soft tissue, neurosurgery, genitourinary, gynecology, and head and neck cancers), adult and pediatric hematologists/medical oncologists, gynecologic oncologists, and radiation oncologists. They, along with more than 600 other cancer healthcare professionals (nurses, pharmacists, nutritionists, navigators, psychologists and social workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner with community health systems statewide to provide cancer care closer to home. They treated 13,578 patients in 105,748 ambulatory clinic visits in addition to in-patient hospitalizations at UNM Hospital. A total of 1361 patients participated in cancer clinical trials, including 544 (40%) who participated in clinical trials testing new cancer treatments that include tests of novel cancer prevention strategies and cancer genome sequencing. The more than 102 cancer research scientists affiliated with the UNMCCC were awarded $36.2 million in federal and private grants and contracts for cancer research projects. Since 2015, they have published 930 manuscripts, and promoting economic development, they filed 136 new patents and launched 10 new biotechnology start-up companies. Finally, the physicians, scientists and staff have provided education and training experiences to more than 530 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery. Learn more at www.cancer.unm.edu.
